The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Ticlid     3-[(2-chlorophenyl)methyl]-7- thia-3...

Synonyms: Ticlopidina, ticlopidine, Ticlopidinum, CHEMBL833, SureCN4204, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.



Psychiatry related information on TICLOPIDINE HYDROCHLORIDE

  • The three-year event rate for nonfatal stroke or death from any cause was 17 percent for ticlopidine and 19 percent for aspirin--a 12 percent risk reduction (95 percent confidence interval, -2 to 26 percent) with ticlopidine (P = 0.048 for cumulative Kaplan-Meier estimates) [5].
  • Individual patient-by-patient analysis shows that patency of all grafts at each study time, is more frequent in the ticlopidine group [6].

High impact information on TICLOPIDINE HYDROCHLORIDE


Chemical compound and disease context of TICLOPIDINE HYDROCHLORIDE






Associations of TICLOPIDINE HYDROCHLORIDE with other chemical compounds




Analytical, diagnostic and therapeutic context of TICLOPIDINE HYDROCHLORIDE

  • In patients examined, these abnormalities resolved upon the remission that accompanied plasma exchange and discontinuation of ticlopidine therapy [34].
  • METHODS AND RESULTS: We randomized 350 high-risk patients within 6 hours after stent implantation to receive during 30 days either aspirin 250 mg and ticlopidine 500 mg/d (A+T group) or aspirin 250 mg/d and oral anticoagulation (A+OAC group) targeted at an international normalized ratio of 2.5 to 3 [35].
  • Two major factors exhibited time-dependent variations of their influence: while residual dissections were the dominant risk factor within the first 3 days with a reduction after that, no protective effect of ticlopidine could be identified before day 3 [36].
  • Thirty patients underwent PTCA; 15 of them were not treated with ticlopidine and 15 were given ticlopidine (> or = 72 h) [13].
  • METHODS: Published data from trials and registries that compared clopidogrel with ticlopidine in patients receiving coronary stents were pooled, and a formal meta-analysis was performed [37].


  1. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. Leon, M.B., Baim, D.S., Popma, J.J., Gordon, P.C., Cutlip, D.E., Ho, K.K., Giambartolomei, A., Diver, D.J., Lasorda, D.M., Williams, D.O., Pocock, S.J., Kuntz, R.E. N. Engl. J. Med. (1998) [Pubmed]
  2. Ticlopidine and thrombotic thrombocytopenic purpura. Kupfer, Y., Tessler, S. N. Engl. J. Med. (1997) [Pubmed]
  3. Ticlopidine and thrombocytopenia. Takishita, S., Kawazoe, N., Yoshida, T., Fukiyama, K. N. Engl. J. Med. (1990) [Pubmed]
  4. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine après Pontage Fémoro-Poplité and the Association Universitaire de Recherche en Chirurgie. Becquemin, J.P. N. Engl. J. Med. (1997) [Pubmed]
  5. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. Hass, W.K., Easton, J.D., Adams, H.P., Pryse-Phillips, W., Molony, B.A., Anderson, S., Kamm, B. N. Engl. J. Med. (1989) [Pubmed]
  6. Prevention of aorta-coronary bypass graft occlusion. Beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. Limet, R., David, J.L., Magotteaux, P., Larock, M.P., Rigo, P. J. Thorac. Cardiovasc. Surg. (1987) [Pubmed]
  7. Thrombotic thrombocytopenic purpura associated with clopidogrel. Bennett, C.L., Connors, J.M., Carwile, J.M., Moake, J.L., Bell, W.R., Tarantolo, S.R., McCarthy, L.J., Sarode, R., Hatfield, A.J., Feldman, M.D., Davidson, C.J., Tsai, H.M. N. Engl. J. Med. (2000) [Pubmed]
  8. Toxic erythroderma due to ticlopidine. Hsi, D.H., Mock, D.J., Rocco, T.A. N. Engl. J. Med. (1999) [Pubmed]
  9. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. Schömig, A., Neumann, F.J., Kastrati, A., Schühlen, H., Blasini, R., Hadamitzky, M., Walter, H., Zitzmann-Roth, E.M., Richardt, G., Alt, E., Schmitt, C., Ulm, K. N. Engl. J. Med. (1996) [Pubmed]
  10. Ticlopidine and TTP after coronary stenting. Bennett, C.L., Davidson, C.J., Green, D., Weinberg, P.D., Feldman, M.D. JAMA (1999) [Pubmed]
  11. The antiplatelet effects of ticlopidine and clopidogrel. Sharis, P.J., Cannon, C.P., Loscalzo, J. Ann. Intern. Med. (1998) [Pubmed]
  12. Recurrent arterial thrombosis linked to autoimmune antibodies enhancing von Willebrand factor binding to platelets and inducing Fc gamma RII receptor-mediated platelet activation. Hoylaerts, M.F., Thys, C., Arnout, J., Vermylen, J. Blood (1998) [Pubmed]
  13. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures. Gregorini, L., Marco, J., Fajadet, J., Bernies, M., Cassagneau, B., Brunel, P., Bossi, I.M., Mannucci, P.M. J. Am. Coll. Cardiol. (1997) [Pubmed]
  14. Phenytoin toxicity associated with ticlopidine administration. Rindone, J.P., Bryan, G. Arch. Intern. Med. (1996) [Pubmed]
  15. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. Steinhubl, S.R., Lauer, M.S., Mukherjee, D.P., Moliterno, D.J., Lincoff, A.M., Ellis, S.G., Topol, E.J. J. Am. Coll. Cardiol. (1998) [Pubmed]
  16. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. Di Minno, G., Cerbone, A.M., Mattioli, P.L., Turco, S., Iovine, C., Mancini, M. J. Clin. Invest. (1985) [Pubmed]
  17. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Bennett, C.L., Weinberg, P.D., Rozenberg-Ben-Dror, K., Yarnold, P.R., Kwaan, H.C., Green, D. Ann. Intern. Med. (1998) [Pubmed]
  18. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Rupprecht, H.J., Darius, H., Borkowski, U., Voigtländer, T., Nowak, B., Genth, S., Meyer, J. Circulation (1998) [Pubmed]
  19. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Ma, L., Elliott, S.N., Cirino, G., Buret, A., Ignarro, L.J., Wallace, J.L. Proc. Natl. Acad. Sci. U.S.A. (2001) [Pubmed]
  20. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind, randomized comparative trial. Spaulding, C., Charbonnier, B., Cohen-Solal, A., Juillière, Y., Kromer, E.P., Benhamda, K., Cador, R., Weber, S. Circulation (1998) [Pubmed]
  21. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. Inoue, T., Uchida, T., Sakuma, M., Imoto, Y., Ozeki, Y., Ozaki, Y., Hikichi, Y., Node, K. J. Am. Coll. Cardiol. (2004) [Pubmed]
  22. Hemolytic uremic syndrome associated with clopidogrel: a case report. Moy, B., Wang, J.C., Raffel, G.D., Marcoux, J.P. Arch. Intern. Med. (2000) [Pubmed]
  23. Ticlopidine improves the enhanced erythrocyte aggregability in patients with cerebral infarction. Tanahashi, N., Fukuuchi, Y., Tomita, M., Matsuoka, S., Takeda, H. Stroke (1993) [Pubmed]
  24. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Donahue, S.R., Flockhart, D.A., Abernethy, D.R., Ko, J.W. Clin. Pharmacol. Ther. (1997) [Pubmed]
  25. Vascular complications and clinical outcome after coronary angioplasty with platelet IIb/IIIa receptor blockade. Comparison of transradial vs transfemoral arterial access. Choussat, R., Black, A., Bossi, I., Fajadet, J., Marco, J. Eur. Heart J. (2000) [Pubmed]
  26. Fatal aplastic anaemia associated with clopidogrel. Trivier, J.M., Caron, J., Mahieu, M., Cambier, N., Rose, C. Lancet (2001) [Pubmed]
  27. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention. Kereiakes, D.J., Runyon, J.P., Kleiman, N.S., Higby, N.A., Anderson, L.C., Hantsbarger, G., McDonald, S., Anders, R.J. Circulation (1996) [Pubmed]
  28. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI stent pilot trial. Primary Angioplasty in Myocardial Infarction Stent Pilot Trial Investigators. Stone, G.W., Brodie, B.R., Griffin, J.J., Morice, M.C., Costantini, C., St Goar, F.G., Overlie, P.A., Popma, J.J., McDonnell, J., Jones, D., O'Neill, W.W., Grines, C.L. J. Am. Coll. Cardiol. (1998) [Pubmed]
  29. A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events. Haynes, R.B., Sandler, R.S., Larson, E.B., Pater, J.L., Yatsu, F.M. Arch. Intern. Med. (1992) [Pubmed]
  30. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. Richter, T., Mürdter, T.E., Heinkele, G., Pleiss, J., Tatzel, S., Schwab, M., Eichelbaum, M., Zanger, U.M. J. Pharmacol. Exp. Ther. (2004) [Pubmed]
  31. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Turpeinen, M., Nieminen, R., Juntunen, T., Taavitsainen, P., Raunio, H., Pelkonen, O. Drug Metab. Dispos. (2004) [Pubmed]
  32. Heterologous expression and kinetic characterization of human cytochromes P-450: validation of a pharmaceutical tool for drug metabolism research. Masimirembwa, C.M., Otter, C., Berg, M., Jönsson, M., Leidvik, B., Jonsson, E., Johansson, T., Bäckman, A., Edlund, A., Andersson, T.B. Drug Metab. Dispos. (1999) [Pubmed]
  33. Parameters of the tissue factor pathway with coumadin/dipyridamole versus ticlopidine as adjunct antithrombotic-drug regimen in coronary artery stenting. Kopp, C.W., Steiner, S., Priglinger, U., Christ, G., Probst, P., Maurer, G., Minar, E., Huber, K. Blood Coagul. Fibrinolysis (2003) [Pubmed]
  34. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Tsai, H.M., Rice, L., Sarode, R., Chow, T.W., Moake, J.L. Ann. Intern. Med. (2000) [Pubmed]
  35. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Urban, P., Macaya, C., Rupprecht, H.J., Kiemeneij, F., Emanuelsson, H., Fontanelli, A., Pieper, M., Wesseling, T., Sagnard, L. Circulation (1998) [Pubmed]
  36. Intracoronary stenting and risk for major adverse cardiac events during the first month. Schühlen, H., Kastrati, A., Dirschinger, J., Hausleiter, J., Elezi, S., Wehinger, A., Pache, J., Hadamitzky, M., Schömig, A. Circulation (1998) [Pubmed]
  37. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. Bhatt, D.L., Bertrand, M.E., Berger, P.B., L'Allier, P.L., Moussa, I., Moses, J.W., Dangas, G., Taniuchi, M., Lasala, J.M., Holmes, D.R., Ellis, S.G., Topol, E.J. J. Am. Coll. Cardiol. (2002) [Pubmed]
WikiGenes - Universities